Evaluating TG Therapeutics: Insights From 4 Financial Analysts
Portfolio Pulse from Benzinga Insights
TG Therapeutics (NASDAQ:TGTX) has received diverse evaluations from analysts, with a majority being bullish. The average 12-month price target has increased to $38.0. The company shows strong financial performance with significant revenue growth and profitability, but faces challenges in debt management.
September 18, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TG Therapeutics has received mostly bullish ratings from analysts, with an increased average price target of $38.0. The company shows strong revenue growth and profitability, but has a higher debt-to-equity ratio than industry averages.
The majority of analysts have a bullish outlook on TG Therapeutics, with an increased average price target, indicating positive sentiment. The company's strong financial performance supports this view, although the high debt-to-equity ratio poses a risk.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100